Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...

Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular ...

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...

"The impact on not just kidney disease but also cardiovascular disease and on all-cause death." Ozempic and other semaglutide injections such as Wegovy have been in short supply for years due to ...